Changchun high and new technology fell to the limit again after yesterday's flash fall, and as of press time, it was quoted at 204.84 yuan, down 10%, changed hands 0.73%, and the turnover was 554 million. The company responded that growth hormone products were included in the drug collection of Guangdong Province: no specific impact is expected at present.
Data from yesterday's Dragon and Tiger list showed that Shenzhen shares sold 97.3 million yuan and bought 278 million yuan, while an institution sold 88.69 million yuan.
In fact, outsiders have been paying more attention to whether Changchun's high-tech growth hormone products will be included in the collection.
On August 16 last year, Zhang Deshen, secretary of Changchun High-tech Dong, talked about this topic in a micro interview with the Securities Times. E Company, said that in view of the current situation, the company does not expect growth hormone products to be collected by the country in the near future. At present, only individual provinces plan to carry out collection projects, which have relatively little impact. Assuming that the collection policy is on the ground and the product price is falling, the company will strive to ensure the company's performance by improving the number of users.
In September of the same year, Changchun Hi-Tech also said on the interactive platform that Recombinant Human growth hormone (rhGH) has always belonged to Class B health insurance, which is limited to primary growth hormone deficiency in children; at present, there is no collection policy.
So, will collection lead to performance stall?
The reason why the above-mentioned news jointly collected by Guangdong is so powerful is that the subsidiary Jinsai Pharmaceutical Co., Ltd. is the "profit cow" of Changchun high-tech, and the recombinant human growth hormone series products are the pillar of Jinsai Pharmaceutical Industry.
In recent years, Changchun's high-tech performance has been growing at a high speed, especially the return net profit has increased from 485 million yuan in 2016 to 3.047 billion yuan in 2020, more than six times. Data show that Jinsai Pharmaceutical achieved a net profit of 2.76 billion yuan in 2020, accounting for 90.58% of Changchun's high-tech net profit. Listed companies previously said on the investor interaction platform that the non-growth hormone business accounted for only about 5% of Jinsai's revenue.
Judging from the current situation, this joint mining includes water needle and powder needle. This means that the water needle, which contributes mainly to revenue and profits, is also in the range of collection this time.
Once the collection of growth hormone is carried out nationwide, then the high-tech performance of Changchun may face a very great impact.
Over the past six months or so, Changchun high-tech stock prices have been in the doldrums, and now they are eating the daily limit again. Glenn, the fund manager known as the "goddess of medicine", just increased his position in Changchun Hi-Tech in November last year. In recent months, the medical theme fund managed by Glenn has stepped on many pharmaceutical stocks, such as Changchun Hi-Tech, Aier Ophthalmology, General Strategy Medical, Wuxi Apptec and so on.
The fund managed by Glenn has always been a "loyal fan" of Changchun Hi-Tech. In the middle of last year, the China-EU mixed Medical and Health Fund held as many as 6.21 million shares in Changchun High-tech. Although in the third quarter of last year, China-EU Healthcare mix at one point reduced its holdings to 5.09 million shares. However, the list of the top 10 shareholders in the company's share buyback announced on November 26 last year showed that as of November 23, China-EU Healthcare mixture had once again increased its position in Changchun Hi-Tech and held 5.51 million shares.
However, after the increase of positions, Changchun high-tech stock prices continued to decline. In fact, in recent months, there has been a lot of thunder in the health care sector of China and Europe. In the early stage, Ayre ophthalmology and general health care fell one after another, and Zhifei reached a new low. Continuously, Wuxi Apptec, Kailiying, Tigermed and other stocks are also not good.